Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT05444348

Compassionate Communication and Advance Care Planning to Improve End of Life Care in Treatment of Hematological Disease (ACT)

Led by Christoffer Johansen · Updated on 2025-07-29

920

Participants Needed

7

Research Sites

217 weeks

Total Duration

On this page

Sponsors

C

Christoffer Johansen

Lead Sponsor

R

Rigshospitalet, Denmark

Collaborating Sponsor

AI-Summary

What this Trial Is About

Patients diagnosed with hematologic cancer are at substantial risk of dying, as 5-year survival among patients with acute myeloid leukemia is 20 % and only every second patient treated for incurable myeloma lives 5 years after date of diagnosis. Nevertheless, many overestimate their prognosis, and value of therapy. Patients with hematological cancers frequently have poor end of life outcomes, such as high treatment activity close to death, where clinical effects are doubtful, and low utilization of palliative care. Prognostic awareness and end of life (EOL) issues have urgency in the communication between patients, their caregiving relatives, and clinicians, in order to avoid futile treatments and suffering at EOL. Inspired by advanced care planning, the investigators developed the concept "Advance Consultations Concerning participants Life and Treatment" (ACT) in collaboration with a group consisting of hematologists, nurses, patients, and caregivers. The ACT concept consists of an 8-hour training day for clinicians, clinical tools, system changes, and preparation material for patients and caregivers prior to the consultation. ACT involves patients and caregivers earlier in preparation for life with chronic progressive disease and EOL-decisions, through an intervention based on compassionate communication and early planning of EOL-care. The aim of the study is to investigate the effect of the intervention on use of chemotherapy and quality of EOL-care in patients with hematological malignancy. Based on the results of the completed pilot study, the investigators are planning a nationwide 2-arm cluster randomized controlled trial where 40 physicians and 80 nurses across seven different hematological departments are randomized to either usual care or ACT training and completing ACT conversations. The investigators expect to include a total of 400 patients and their family caregivers. It is hypothesized that the ACT intervention will decrease use of futile chemotherapy, prepare patients and caregivers for difficult end-of-life-decisions, and improve quality of end-of-life care in hematology.

CONDITIONS

Official Title

Compassionate Communication and Advance Care Planning to Improve End of Life Care in Treatment of Hematological Disease (ACT)

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Be at least 18 years old
  • Diagnosed with high-risk myelodysplastic syndrome or myelodysplastic syndrome with overlap of myeloproliferative neoplasms
  • Diagnosed with acute myeloid leukemia and aged 80 or older, or in palliative treatment, or experiencing relapse
  • Diagnosed with lymphoma and aged 80 or older, or experiencing relapse, refractory disease, or in palliative treatment
  • Diagnosed with multiple myeloma and aged 80 or older, or relapsed, or refractory
  • Have limited treatment options
  • Provide informed consent
  • Have sufficient Danish skills to complete intervention sessions and data collection
  • Have an informal caregiver who is at least 18 years old, can accompany to appointments, provides informed consent, and has sufficient Danish skills
  • Physicians specialized in hematology treating the above patients and working at the same department for the entire intervention period
  • Nurses treating the above patients and working at the same department for the entire intervention period
Not Eligible

You will not qualify if you...

  • Patient or caregiver suffering from a severe psychiatric disorder
  • Physicians or nurses who do not meet the inclusion criteria

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 7 locations

1

Aalborg Universitetshospital

Aalborg, Denmark, 9100

Actively Recruiting

2

Aarhus Universitetshospital

Aarhus, Denmark, 8200

Actively Recruiting

3

Sydvestjysk sygehus - Esbjerg

Esbjerg, Denmark, 6700

Actively Recruiting

4

Regionshospitalet Gødstrup

Herning, Denmark, 7400

Actively Recruiting

5

Odense Universitetshospital

Odense, Denmark, 5000

Actively Recruiting

6

Sjællands universitetshospital Roskilde

Roskilde, Denmark, 4000

Actively Recruiting

7

Lillebælt syge - Vejle Sygehus

Vejle, Denmark, 7100

Actively Recruiting

Loading map...

Research Team

C

Cæcilie Borregaard Myrhøj, MScN

CONTACT

A

Annika von Heymann, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

SUPPORTIVE_CARE

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here